SPARCC Abstracts and Publications

Transcription

1 SPARCC Abstracts and Publications 2006 Papers 1. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis online 2006; Rahman P, Siannis F, Butt C, Farewell F, Peddle L, Pellett F, Gladman D. TNF-α polymorphisms and risk of psoriatic arthritis in Caucasian populations. Ann Rheum Dis 2006;65: Maksymowych WP, Rahman P, Reeve J, Gladman D, Peddle L, Inman RD. The interleukin-1 locus is associated with susceptibility to ankylosing spondylitis: a spondyloarthritis research consortium of Canada (SPARCC) analysis of 3 Canadian populations. Arthritis Rheum 2006;54: Butt C, Gladman D, Rahman P. PPAR-gamma Gene Polymorphisms and Psoriatic Arthritis. J Rheumatol 2006;33: Rahman P, Sun S, Peddle L, Snelgrove T, Melay B, Greenwood C, Gladman D. Association of IL-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006;54: Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis J, Dijkmans B, Dougados M, Géher P, Inman R, Khan A, Kvien T, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock R, van der Linden S, Wendling D, Böhm H, van Royen BJ and Braun J. ASAS/eular recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: , Inman RD. Infection and spondyloarthritis. Nature Rheumatol 2: , Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis J, Dijkmans B, Dougados Géher P, Inman R, Khan A, Kvien T, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock R, van der Linden S, Wendling D, Böhm H, van Royen BJ and Braun J. ASAS/EULAR Recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: , Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A: Etanercept in early-onset ankylosing spondylitis. J Rheumatol 33: , Kim TH, Inman RD. Biomarkers in Spondyloarthritis. Arthritis Rheum 54: , Na KS, Kim TH, Inman RD. Biomarkers in spondyloarthritis. Curr Rheumatol Rep 8: , 2006 SPARCC Publications Nov 2011 Page 1 of 8

2 12. Tsui HW, Inman RD, Reveille JD, Tsui FWL. TNAP variants associated with ankylosing spondylitis. Arthritis Rheum 56: , Kobelt G, Andlin-Sobocki P, Maksymowych W. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 33: , Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 33: , Maksymowych WP, Landewe R. Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol 20:507-19, Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 33:558-61, Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 54(3):974-85, Maksymowych WP, Lambert RGW. Spinal inflammation in ankylosing spondylitis-how and why should it be measured by MRI? Nat Clin Pract Rheumatol 2(5): 232-3, Ritchlin CT, Maksymowych WP. MRI outcomes in AS patients after two years of etanercept therapy. Current Rheumatol Rep 8(4): 253-4, Maksymowych WP, Mallon C, Richardson R, Conner-Spady B, Jauregui E, Chung C, Zappala L, Pile K, Russell AS. Development and validation of the Edmonton ankylosing spondylitis metrology index (EDASMI). Arthritis Rheum 55(4): , Maksymowych WP, Mallon C, Richardson R, Conner-Spady B, Jauregui E, Chung C, Zappala L, Pile K, Russell AS. Development and validation of a simple tape-based measurement tool for recording cervical rotation in patients with ankylosing spondylitis: comparison with a goniometer-based approach. J Rheumatol 33 (11): 2242, Maksymowych WP, Mallon C, Richardson R, Conner-Spady B, Chung C, Russell AS. Does height have an impact on the assessment of spinal and hip mobility measures used in ankylosing spondylitis? J Rheumatol 33(10): , Newman Wg, Zhang Q, Liu X, walker E, Ternan H, Owen J, Johnson B, Greer W, Mosher DP, Maksymowych WP. Rheumatoid arthritis association with the FCRL3 169C polymorphism is restricted to PTPN T homozygous individuals in a Canadian population. Arthritis Rheum 54 (12): , 2006 Abstracts 1. Butt C, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Lack of association of functional variants of PTPN22 and tp53 in psoriatic arthritis: A case-control study. Arthritis Research & Therapy 2006;8:R27. SPARCC Publications Nov 2011 Page 2 of 8

3 2. Gladman DD, Inman RD, Cook RJ, Maksymowych W, van der Heijde D, Landewé R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. The INSPIRE Study Group. International Spondyloarthritis Inter-Observer Reliability Exercise The INSPIRE Study. Arthritis Rheum 2006:54(Suppl 9):S Maksymowych WP, Olczynski W, Sampalis J, Shojani. The Maastricht and Spondyloarthritis Research Consortium of Canada enthesitis scores (mases and spent): A comparison of their reliability and responsiveness. J Rheumatol 33(2); 382, Lambert RGW, Salonen D, Rahman P, Inman R, Wong R, Patra K, Thomson GTD, Beaulieu A, Choquette D, Maksymowych WP. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS) 52 week magnetic resonance imaging (MRI) results from The Canadian AS Study. Ann Rheum Dis 65(suppl 11): 65, Maksymowych WP, Olszynski W, Sampalis J, Ostojic H. The Spondyloarthritis Research Consortium of Canada and Maastricht enthesitis scores (spent and mases): A comparison of their reliability and responsiveness. Ann Rheum Dis 65(suppl 11): 535, Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V,Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. The INSPIRE Study Group. Evaluating enthesitis in patients with spondyloarthritis (SpA). Arthritis Rheum 54 (suppl 9): S724, Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V,Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. International spondyloarthritis inter-observer reliability exercise the INSPIRE Study. Arthritis Rheum 54 (suppl 9): S724, Braun J, Cook R, Gladman D, Inman R, Maksymowych W, Landewe, Mease P, Davis J, van der Heijde D, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan MA, O Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. INSPIRE spondyloarthritis. Arthritis Rheum 54 (suppl 9): S476, Proton R, Inman R, Gladman D, Reeve J, Sooyeol L, Greenwood C, Peddle L, Sun S, Maksymowych W for the SPARCC Consortium. Fine mapping of -200kb region centromeric to IL-1A identifies two novel regions associated with disease risk in spondyloarthropathies. Arthritis Rheum 54 (suppl 9): S714, Inman RD, Shojania K, Keystone E, Haraoui B, Leombruno JP, Maksymowych WP. Efficacy of lower dose infliximab in active ankylosing spondylitis interim results of a Canadian study. Arthritis Rheum 54 (suppl 9): S471, Braun J, Cook R, Landewe R, Gladman DD, Inman RD, Maksymowych W, Mease P, Davis J, Van der Heijde D, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan M, O Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. INSPIRE SPARCC Publications Nov 2011 Page 3 of 8

4 spondyloarthritis (SPA). Ann Rheum Dis 65(suppl 11): 208, Gladman DD, Inman RD, Cook RR, Maksymowych W, Van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille RD, Stone M, Taylor W, Veale DJ. International spondyloarthritis inter-observer reliability exercise the INSPIRE study. Ann Rheum Dis 65(suppl 11): 217, Maksymowych WP, Cook RJ, Landewé R, Gladman DG, Iman RD, Braun J, Mease PJ, Davis JC, van der Heijde D, for the INSPIRE study group. INSPIRE Hip Mobility: A new method to measure hip mobility in patients with rheumatic diseases. Arthritis Rheum 54 (suppl 9): S473, Lambert RGW, Salonen DC, Rahman P, Inman RD, Wong R, Patra K, Thomson GTD, Beaulieu AD, Choquette D, Maksymowych WP. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS): 52-week magnetic resonance imaging (MRI) results from the Canadian AS Study. Arthritis Rheum 54 (suppl 9): S799, Maksymowych WP, Olczynski W, Sampalis J, Shojani. The Maastricht and Spondyloarthritis Research Consortium of Canada enthesitis scores (mases and spent): A comparison of their reliability and responsiveness. J Rheumatol 33(2); 382, Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. J Rheumatol 33(2); 381, Lambert RGW, Salonen D, Rahman P, Inman R, Wong R, Patra K, Thomson GTD, Beaulieu A, Choquette D, Maksymowych WP. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS) 52 week magnetic resonance imaging (MRI) results from The Canadian AS Study. Ann Rheum Dis 65(suppl 11): 65, Boonen A, Kobelt G, Richardson R, Mallon C, Maksymowych WP. Pharmaco-economic benefits of attaining a patient acceptable symptom state (PASS) in patients with ankylosing spondylitis (AS). Ann Rheum Dis 65(suppl 11): 284, Rennie WJ, Shillon SS, Conner-Spady B, Maksymowych WP. Standard MRI assessment of spinal inflammatory lesions in AS may omit a significant component of inflammation in the thoracic spine. Ann Rheum Dis 65(suppl 11): 534, Maksymowych WP, Olszynski W, Sampalis J, Ostojic H. The Spondyloarthritis Research Consortium of Canada and Maastricht enthesitis scores (spent and mases): A comparison of their reliability and responsiveness. Ann Rheum Dis 65(suppl 11): 535, Sims A-M., Timms AE, Pointon J, Chou CT, Gladman DD, Inman R, Maksymowych W, Rahman P, Reveille JD, Wordsworth BP, Xu H, Gergely P, Brown MA, and the International Genetics of Ankylosing Spondylitis Consortium. IL-1 gene family members are associated with ankylosing spondylitis in both Caucasian and Asian populations. Clin Exp Rheumatol 24(4): 463, Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Østergaard M, Oostveen A, O Connor P, Maksymowych W, Lambert RG, Jurik AG, Baraliakos X, Landewé R for the SPARCC Publications Nov 2011 Page 4 of 8

5 ASAS/OMERACT MRI in AS working group. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis. A multi-reader experiment. Clin Exp Rheumatol 24(4): 473, Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, Poole AR,Wang N, Van der Heijde D. Serum Matrix Metalloproteinase 3 is an Independent Predictor of Structural Damage Progression in Patients with Ankylosing Spondylitis (AS). Clin Exp Rheumatol 24(4): 473, Lambert RGW, Salonen D, Rahman P, Inman R, Wong R, Patra K, Thomson GTD, Beaulieu A, Choquette D, Maksymowych WP. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS) 52 week magnetic resonance imaging (MRI) results from The Canadian AS Study. Clin Exp Rheumatol 24(4): 468, Maksymowych WP, Rennie WJ, Dhillon SS, Conner-Spady B, Lambert GW. Is the costovertebral joint the primary site of inflammation in the thoracic spine of patients with ankylosing spondylitis?a systemic evaluation by MRI. Clin Exp Rheumatol 24: 465, Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V,Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. The INSPIRE Study Group. Evaluating enthesitis in patients with spondyloarthritis (SpA). Arthritis Rheum 54 (suppl 9): S724, Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V,Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. International spondyloarthritis inter-observer reliability exercise the INSPIRE Study. Arthritis Rheum 54 (suppl 9): S724, Braun J, Cook R, Gladman D, Inman R, Maksymowych W, Landewe, Mease P, Davis J, van der Heijde D, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan MA, O Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. INSPIRE spondyloarthritis. Arthritis Rheum 54 (suppl 9): S476, Proton R, Inman R, Gladman D, Reeve J, Sooyeol L, Greenwood C, Peddle L, Sun S, Maksymowych W for the SPARCC Consortium. Fine mapping of -200kb region centromeric to IL-1A identifies two novel regions associated with disease risk in spondyloarthropathies. Arthritis Rheum 54 (suppl 9): S714, Inman RD, Shojania K, Keystone E, Haraoui B, Leombruno JP, Maksymowych WP. Efficacy of lower dose infliximab in active ankylosing spondylitis interim results of a Canadian study. Arthritis Rheum 54 (suppl 9): S471, Braun J, Cook R, Landewe R, Gladman DD, Inman RD, Maksymowych W, Mease P, Davis J, Van der Heijde D, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan M, O Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. INSPIRE spondyloarthritis (SPA). Ann Rheum Dis 65(suppl 11): 208, SPARCC Publications Nov 2011 Page 5 of 8

6 31. Gladman DD, Inman RD, Cook RR, Maksymowych W, Van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O Shea FD, Khan MA, Pipitone N, Rahman P, Reveille RD, Stone M, Taylor W, Veale DJ. International spondyloarthritis inter-observer reliability exercise the INSPIRE study. Ann Rheum Dis 65(suppl 11): 217, Maksymowych WP, Wang N, Elewaut D, Reeve J. Polymorphism in an IL18 promotor may influence susceptibility to ankylosing spondylitis. Arthritis Rheum 54 (suppl 9): S467, Maksymowych WP, Cook RJ, Landewé R, Gladman DG, Iman RD, Braun J, Mease PJ, Davis JC, van der Heijde D, for the INSPIRE study group. INSPIRE Hip Mobility: A new method to measure hip mobility in patients with rheumatic diseases. Arthritis Rheum 54 (suppl 9): S473, Maksymowych WP, Rennie WJ, Dhillon SS, Conner-Spady B, Lambert, RGW. In the costovertebral the primary site of inflammation in the thoracic spine of patients with ankylosing spondylitis? Arthritis Rheum 54 (suppl 9): S474, Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, Poole AR,Wang N, Van der Heijde D. Serum Matrix Metalloproteinase 3 is an Independent Predictor of Structural Damage Progression in Patients with Ankylosing Spondylitis (AS). Arthritis Rheum 54 (suppl 9): S512, Crowther SM, Lambert RGW, Dhillon SS, Maksymowych WP. High frequency of inflammatory lesions in the posterior structures of the spine in patients with ankylosing spondylitis (AS): A systematic evaluation by MRI. Arthritis Rheum 54 (suppl 9): S793, Lukas C, Braun J, van der Heijde D, Hermann K-G, Rudwaleit M, Østergaard M, Oostveen A, O Connor P, Maksymowych W, Lambert RG, Jurik AG, Baraliakos X, Landewé, R. The ASAS/OMERACT MRI in AS working group. Scoring inflammation of the spine in ankylosing spondylitis by MRI. A multi-reader experiment. Arthritis Rheum 54 (suppl 9): S799, Lambert RGW, Salonen DC, Rahman P, Inman RD, Wong R, Patra K, Thomson GTD, Beaulieu AD, Choquette D, Maksymowych WP. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS): 52-week magnetic resonance imaging (MRI) results from the Canadian AS Study. Arthritis Rheum 54 (suppl 9): S799, O Shea FD, Salonen D, Ammedolia C, Hsu W, Peterson C, Inman RD. Front-line back pain: the prevalence of sacroiliac joint disease in a primary back pain cohort. Arthritis Rheum 54: S715, O Shea FD, Tsui FW, Tsui HW, Chiu B, Yazdanpanah M, Inman RD. Serum retinol levels are decreased in ankylosing spondylitis and are independent of disease activity. Arthritis Rheum 54: S715, Chandran V, O Shea FD, Schentag CT, Gladman D, Inman RD. Structure-function relationships in the spine: a systematic analysis in ankylosing spondylitis and psoriatic arthritis. Arthritis Rheum 54: S717, SPARCC Publications Nov 2011 Page 6 of 8

7 42. Smith JA, Barnes MG, Hong D, DeLay ML, Inman RD, Colbert RA. Preliminary definition of a gene expression signature in macrophages from ankylosing spondylitis patients. Arthritis Rheum 54: S810, Chandran V, O'Shea F, Schentag CT, Gladman DD, Inman RD, for the INSPIRE Study Group. Structure-Function relationships in the spine: a systematic analysis in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Arthritis Rheum 2006:54(Suppl 9):S Rahman P, Peddle L, Lim S, Greenwood C, Pellett F, Gladman D. Fine mapping via DNA pooling between CDSN and TNF-alpha in PsA reveals two novel regions. Arthritis Rheum 2006:54(Suppl 9):S Chandran V, Schentag CT, Gladman DD. CASPAR Criteria are sensitive in early psoriatic arthritis. Arthritis Rheum 2006:54(Suppl 9):S Ali Y, Tom B, Schentag CT, Farewell VT, Gladman DD. Did mortality rate improve in psoriatic arthritis (PsA) Arthritis Rheum 2006:54(Suppl 9):S Rohekar S, Tom BDM, Hassa A, Farewell VT, Schentag CT, Gladman DD. No increased malignancy risk in psoriatic arthritis (PsA). Arthritis Rheum 2006:54(Suppl 9):S Gladman DD, Inman RD, Cook RJ, Maksymowych W, van der Heijde D, Landewé R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. Evaluating enthesitis in patients with spondyloarthritis (SPA): Results from the International Spondyloarthritis Interobserver Reliability Exercise The INSPIRE Study. Arthritis Rheum 2006:54(Suppl 9):S Rahman P, Inman R, Gladman D, Reeve J, Lim S, Greenwood C, Peddle L, Sun S, Maksymowych WP. Fine mapping of ~200kb region centromeric to IL-1A identifies two novel regions associated with disease risk in spondyloarthropathies. Arthritis Rheum 2006:54(Suppl 9):S Rahman P, Peddle L, Greenwood C, Pellett F, Gladman D. Fine mapping using DNA pooling in PsA identifies a novel critical region independent of HLA-Cw6 in the MHC region. Ann Rheum Dis 2006;65(Suppl II): Gladman DD, Mease PJ, Choy ESH, Ritchlin CT, Wang H, Sasso EH. Adalimumab radiographic efficacy in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use, and clinical response. Subanalyses of ADEPT. Arthritis Rheum 2006:54(Suppl 9):S Braun J, Cook R, Landewé R, Gladman DD, Inman RD, Maksymowych W, Mease P, Davis J, van der Heijde D, Brandt J, Buros Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan M, O-Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. INSPIRE spondyloarthritis (SPA). Ann Rheum Dis 2006;65(Suppl II): Braun J, Cook R, Gladman DD, Inman R, Maksymowych W, Landewé R, Mease P, Davis JC, van der Heijde D, Brandt J, Burgos-Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan MA, O Shea F, Pipitone N, Rahman P, Reveille J, Stone M, Taylor W, Veale D. INSPIRE SPARCC Publications Nov 2011 Page 7 of 8

8 Lateral Flexion: A new method to measure lateral spinal mobility in patients with spondyloarthritis. Arthritis Rheum 2006:54(Suppl 9):S Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy fatigues scale in psoriatic arthritis: a validation study. Ann Rheum Dis 2006;65(Suppl II): Choy E, Gladman DD, Sasso E. Adalimumab is efficacious in treating joint disease in early and established psoriatic arthritis: subanalysis of ADEPT. Ann Rheum Dis 2006;65(Suppl II): Gladman DD, Inman RD, Cook R, Maksymowych W, Landewé R, van der Heijde D, Braun J, Davis J, Mease P, Brandt J, Buros Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan M, O-Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. International Spondyloarthritis Inter-observer Reliability Exercise The INSPIRE study. Ann Rheum Dis 2006;65(Suppl II): Gladman D, Mease P, Kavanaugh A, Weinberg M. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: Subanalysis of moderate versus severe psoriasis in the ADEPT trial. J Am Acad Dermatol 2006:54(Suppl 1):AB Mease PJ, Gladman DD, Ritchlin CT, Weinberg MA. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial. J Am Acad Dermatol 2006:54(suppl 1):AB Gladman D, Mease P, Chmiel J, Mellili L. Complete resolution of arthritis and dermatologicrelated functional loss with adalimumab in patients with psoriatic arthritis. J Am Acad Dermatol 2006:54(suppl 1):AB Gladman DD. Functional assessment in psoriatic arthritis (PsA). Ann Rheum Dis 2006;65(Suppl II): Schentag C, Gladman D. Comparison of patient-physician perceptions of disease activity in psoriatic arthritis (PsA). J Rheumatol 2006; 33: Rohekar S, Hassa A, Schentag C, Gladman D. Malignancy in psoriatic arthritis (PsA). J Rheumatol 2006; 33: Butt C, Hamilton S, Gladman D, Rahman P. PPAR-gamma coding polymorphisms not associated with psoriatic arthritis in a Caucasian population. J Rheumatol 2006; 33: Snelgrove T, Gladman D, Zipperlen K, Sun S, Greendwood C, Peddle L, Rahman P. Association of STAT3 variants and PSA no evidence for association in two independent Caucasian populations. J Rheumatol 2006:33: Ali Y, Tom B, Schentag C, Farewell V, Gladman D. Did mortality rate improve in psoriatic arthritis (PsA) patients in the last decade? J Rheumatol 2006; 33:386. SPARCC Publications Nov 2011 Page 8 of 8